References
- Baker, G. P., Gibbons, R., & Murphy, K. J. (2008). Strategic alliances: Bridges between “islands of conscious power”. Journal of Japanese and International Economies, 22(2), 146–163. doi:10.1016/j.jjie.2008.03.001
- Berndt, E. R., Nass, D., Kleinrock, M., & Aitken, M. (2015). Decline in economic returns from new drugs raises questions about sustaining innovations. Health Affairs, 34(2), 245–252. doi:10.1377/hlthaff.2014.1029
- Block, J., De Vries, G., & Sandner, P. (2010). Venture capital and the financial crisis: An empirical study across industries and countries. In D. Cumming (Ed.), The oxford handbook of venture capital (pp. 37–61). Oxford University Press.
- Cambridge Associates (2017). PE/VC impact investing index & benchmark statistics. Retrieved from https://www.cambridgeassociates.com/benchmarks/ (accessed on November 20, 2017).
- Chiampou, G. F., & Kallett, G. F. (1989). Risk/return profile of venture capital. Journal of Business Venturing, 4(1), 1–10. doi:10.1016/0883-9026(89)90030-X
- Deloitte, L. L. P. (2014). Measuring the return from pharmaceutical innovation 2014: Turning the corner? Retrieved from https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/measuring-the-return-from-pharmaceutical-innovation-2014.html (accessed on October 5, 2017).
- DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010). Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics, 87(3), 272–277. doi:10.1038/clpt.2009.295
- Downing, N. S., Zhang, A. D., & Ross, J. S. (2017). Regulatory review of new therapeutic agents – FDA versus EMA, 2011–2015. New England Journal of Medicine, 376(14), 1386–1387.
- Fleming, J. J. (2015). The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation. Health Affairs, 34, 270–276.
- Invest Europe (2017). European Private Equity. Statistics on Fundraising, Investments and Divestments. available at: https://www.investeurope.eu/media/711867/Invest-Europe-2017-European-Private-Equity-Activity.pdf (accessed on October 5, 2017).
- Janssen Health Policy Center (2015). Investing in the future of health. Retrieved from http://www.janssen-emea.com/node/1154 (accessed on October 2, 2017).
- KPMG (2017). Venture Pulse. Retrieved from https://assets.kpmg.com/content/dam/kpmg/xx/pdf/2018/01/venture-pulse-report-q4-17.pdf (accessed on October 15, 2018).
- Lazonick, W., & Tulum, O. (2011). US biopharmaceutical finance and the sustainability of the biotech business model. Research Policy, 40(9), 1170–1187. doi:10.1016/j.respol.2011.05.021
- Lazonick, W., & Mazzucato, M. (2013). The risk-reward nexus in the innovation-inequality relationship: who takes the risks? who gets the rewards? Industrial and Corporate Change, 22(4), 1093–1128. doi:10.1093/icc/dtt019
- OECD (2017). Entrepreneurship at a Glance 2017. Retrieved from https://doi.org/10.1787/22266941 (accessed on October 15, 2018).
- Politico (2015). Are levels of health R&D investment in Europe sufficient to cope with health challenges? Retrieved from https://www.politico.eu/sponsored-content/are-levels-of-health-rd-investment-in-europe-suffi-cient-to-cope-with-health-challenges/ (accessed on October 5, 2017).
- PWC/CB Insights (2018). MoneyTree report. Retrieved from: https://www.pwc.com/us/en/moneytree-report/moneytree-report-q3-2018.pdf (Accessed on October 20, 2018).
- Reiner, U. H. (2013). Determinants of venture capital performance – empirical evidence (PhD dissertation), Technische Universität München, Munich. Retrieved from https://d-nb.info/104587888X/34 (accessed on October 2, 2017).
- Schwienbacher, A. (2008). An empirical analysis of venture capital exits in Europe and in the United States. Financial Markets and Portfolio Management, 22(3), 195–217. DOI 10.1007/s11408-008-0080-z doi:10.1007/s11408-008-0080-z